Prostate Cancer Biochemical Recurrence Resulted Negative on [Ga]Ga-PSMA-11 but Positive on [F]Fluoromethylcholine PET/CT

Overview

Journal Tomography

Publisher MDPI

Specialty Radiology

Date 2022 Oct 26

PMID 36287804

Authors

Riccardo Laudicella

Flavia La Torre

Valerio Davi

Ludovica Croce

Demetrio Arico

Giuseppe Leonardi

Simona Russo

Fabio Minutoli

Irene A Burger

Sergio Baldari

Affiliations

Soon will be listed here.

Abstract

For prostate cancer (PCa) biochemical recurrence (BCR), the primarily suggested imaging technique by the European Association of Urology (EAU) guidelines is prostate-specific membrane antigen (PSMA) positron emission tomography/computer tomography (PET/CT). Indeed, the increased detection rate of PSMA PET/CT for early BCR has led to a fast and wide acceptance of this novel technology. However, PCa is a very heterogeneous disease, not always easily assessable with the highly specific PSMA PET with around 10% of cases occuring without PSMA expression. In this paper, we present the case of a patient with PCa BCR that resulted negative on [Ga]Ga-PSMA-11 PET/CT, but positive on [F]Fluoromethylcholine (Choline) PET/CT.

Citing Articles

The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer.

Laudicella R, Bauckneht M, Burger I, Cacciola A, Fanti S, Farolfi A Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39934300 DOI: 10.1007/s00259-025-07083-8.

mCRPC progression of disease after [Lu]Lu-PSMA-617 detected on [F]Choline: a case of PCa heterogeneity.

Laudicella R, Minutoli F, Russo S, Siracusa M, Bambaci M, Pagano B Urol Case Rep. 2024; 54:102750.

PMID: 38765461 PMC: 11101952. DOI: 10.1016/j.eucr.2024.102750.

Choline PET/CT in recurrent prostate cancer.

Detti B, Carnevale M, Lucidi S, Burchini L, Caini S, Orsatti C Front Oncol. 2023; 13:1079808.

PMID: 37025599 PMC: 10070677. DOI: 10.3389/fonc.2023.1079808.

Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with Ga-PSMA PET/CT Features in Primary Staging.

Vetrone L, Mei R, Bianchi L, Giunchi F, Farolfi A, Castellucci P Cancers (Basel). 2023; 15(6).

PMID: 36980602 PMC: 10046634. DOI: 10.3390/cancers15061716.

Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics.

Laudicella R, Spataro A, Croce L, Giacoppo G, Romano D, Davi V Diagnostics (Basel). 2023; 13(6).

PMID: 36980482 PMC: 10047910. DOI: 10.3390/diagnostics13061175.

References

Yadav S, Stockert J, Hackert V, Yadav K, Tewari A . Intratumor heterogeneity in prostate cancer. Urol Oncol. 2018; 36(8):349-360. DOI: 10.1016/j.urolonc.2018.05.008. View

Morigi J, Stricker P, van Leeuwen P, Tang R, Ho B, Nguyen Q . Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med. 2015; 56(8):1185-90. DOI: 10.2967/jnumed.115.160382. View

Alberts I, Sachpekidis C, Fech V, Rominger A, Afshar-Oromieh A . PSMA-negative prostate cancer and the continued value of choline-PET/CT. Nuklearmedizin. 2019; 59(1):33-34. DOI: 10.1055/a-1044-1855. View

Barbaud M, Frindel M, Ferrer L, Le Thiec M, Rusu D, Rauscher A . 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes. Prostate. 2018; 79(5):454-461. DOI: 10.1002/pros.23751. View

Kesch C, Yirga L, Dendl K, Handke A, Darr C, Krafft U . High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics. Eur J Nucl Med Mol Imaging. 2021; 49(1):385-389. PMC: 8712308. DOI: 10.1007/s00259-021-05423-y. View

Gandaglia G, Leni R, Bray F, Fleshner N, Freedland S, Kibel A . Epidemiology and Prevention of Prostate Cancer. Eur Urol Oncol. 2021; 4(6):877-892. DOI: 10.1016/j.euo.2021.09.006. View

Afshar-Oromieh A, Zechmann C, Malcher A, Eder M, Eisenhut M, Linhart H . Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2013; 41(1):11-20. PMC: 3843747. DOI: 10.1007/s00259-013-2525-5. View

Rosar F, Ribbat K, Ries M, Linxweiler J, Bartholoma M, Maus S . Neuron-specific enolase has potential value as a biomarker for [F]FDG/[Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients. EJNMMI Res. 2020; 10(1):52. PMC: 7246282. DOI: 10.1186/s13550-020-00640-2. View

Emmett L, Metser U, Bauman G, Hicks R, Weickhardt A, Davis I . Prospective, Multisite, International Comparison of F-Fluoromethylcholine PET/CT, Multiparametric MRI, and Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient.... J Nucl Med. 2018; 60(6):794-800. PMC: 6581227. DOI: 10.2967/jnumed.118.220103. View

10.

Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K . Comparison of Ga-labelled PSMA-11 and C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging. 2016; 44(1):92-101. DOI: 10.1007/s00259-016-3490-6. View

11.

Mazzola R, Francolini G, Triggiani L, Napoli G, Cuccia F, Nicosia L . Metastasis-directed Therapy (SBRT) Guided by PET-CT F-CHOLINE Versus PET-CT Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness. Clin Genitourin Cancer. 2020; 19(3):230-236. DOI: 10.1016/j.clgc.2020.08.002. View

12.

Cornford P, van den Bergh R, Briers E, Van den Broeck T, Cumberbatch M, De Santis M . EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2020; 79(2):263-282. DOI: 10.1016/j.eururo.2020.09.046. View

13.

Witkowska-Patena E, Gizewska A, Dziuk M, Misko J, Budzynska A, Walecka-Mazur A . Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer. Clin Nucl Med. 2019; 44(12):e629-e633. DOI: 10.1097/RLU.0000000000002794. View

14.

Laudicella R, Albano D, Alongi P, Argiroffi G, Bauckneht M, Baldari S . F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019; 11(9). PMC: 6769578. DOI: 10.3390/cancers11091348. View

15.

Laudicella R, Ruschoff J, Ferraro D, Brada M, Hausmann D, Mebert I . Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI. Eur J Nucl Med Mol Imaging. 2022; 49(11):3917-3928. PMC: 9399036. DOI: 10.1007/s00259-022-05787-9. View

16.

Mottet N, van den Bergh R, Briers E, Van den Broeck T, Cumberbatch M, De Santis M . EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2020; 79(2):243-262. DOI: 10.1016/j.eururo.2020.09.042. View

17.

Baratto L, Duan H, Laudicella R, Toriihara A, Hatami N, Ferri V . Physiological Ga-RM2 uptake in patients with biochemically recurrent prostate cancer: an atlas of semi-quantitative measurements. Eur J Nucl Med Mol Imaging. 2019; 47(1):115-122. DOI: 10.1007/s00259-019-04503-4. View

18.

Bauckneht M, Bertagna F, Donegani M, Durmo R, Miceli A, De Biasi V . The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients. Prostate Cancer Prostatic Dis. 2021; 24(4):1198-1207. PMC: 8616756. DOI: 10.1038/s41391-021-00391-8. View

19.

Ruschoff J, Ferraro D, Muehlematter U, Laudicella R, Hermanns T, Rodewald A . What's behind Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. Eur J Nucl Med Mol Imaging. 2021; 48(12):4042-4053. PMC: 8484204. DOI: 10.1007/s00259-021-05501-1. View